Post-earnings recap
Reported
Tue, Nov 4, 2025
EPS actual
$1.33
EPS est.
$0.00
EPS surprise
+66400.00%
1-day move
-2.81%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
IDEAYA Biosciences reported a significant EPS beat, but the stock fell by 2.81% following the announcement. The lack of revenue data and guidance may have contributed to investor caution. Overall, while the EPS figure is impressive, uncertainty around revenue could be weighing on investor sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.33 | N/A | +66400.00% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS performance, highlighting their commitment to ongoing projects. However, they did not offer specific revenue guidance.
We are pleased with our EPS results this quarter.
While we did not provide revenue guidance, we are focused on our strategic initiatives.